Carrie Langlais Furr, PhD
VP Regulatory Affairs
Carrie-Lynn Langlais Furr, PhD, RAC, is Vice President of Regulatory Affairs and Program Management at AmpliPhi Biosciences, a clinical-stage biotechnology company focused on the development of bacteriophage-based therapies for the treatment of antibiotic-resistant bacterial infections. Dr. Furr has over a decade of integrated product development and regulatory affairs experience. Prior to joining AmpliPhi, Dr. Furr served as Senior Director of Operations at Rho, Inc., a clinical research organization, where she also held leadership roles in regulatory affairs, integrated development, program management, and medical writing, which stemmed from her early years in regulatory operations at PPD. Dr. Furr’s experience includes providing strategic and operational support through all phases of clinical development, including formal interactions and negotiations with regulatory authorities as well significant contributions to FDA market approval of 5 drugs and a biologic-device combination product. She received a PhD from Texas A & M University in biochemistry and biophysics and studied the antibiotic mechanism of bacteriophages. With AmpliPhi, Dr. Furr is applying her bacteriophage basic research knowledge to treat patients with serious or life-threatening bacterial infections Under Expanded Access regulations, as well as under traditional development pathways.